Feedback

Cellular mechanism of action of forsythiaside for the treatment of diabetic kidney disease

Affiliation
Department of Endocrinology ,Shandong Provincial Hospital Affiliated to Shandong First Medical University ,Jinan ,China
Xu, Chunmei;
Affiliation
Department of Endocrinology ,Shandong Provincial Hospital Affiliated to Shandong First Medical University ,Jinan ,China
Miao, Huikai;
Affiliation
Shandong Provincial Institute of Dermatology and Venereology ,Shandong University ,Jinan ,China
Chen, Xiaoxuan;
Affiliation
Department of Endocrinology ,Shandong Provincial Hospital Affiliated to Shandong First Medical University ,Jinan ,China
Zhang, Haiqing

Background: Diabetic kidney disease (DKD) becomes the leading cause of death for end-stage renal disease, whereas the potential mechanism is unclear and effective therapy is still rare. Our study was designed to investigate the cellular mechanism of Forsythiaside against DKD. Materials and Methods: The targets of Forsythiaside and the DKD-related targets were obtained from databases. The overlapping targets in these two sets were regarded as potential targets for alleviation of DKD by Forsythiaside. The targets of diabetic podocytopathy and tubulopathy were also detected to clarify the mechanism of Forsythiaside ameliorating DKD from the cellular level. Results: Our results explored that PRKCA and RHOA were regarded as key therapeutic targets of Forsythiaside with excellent binding affinity for treating DKD podocytopathy. Enrichment analysis suggested the underlying mechanism was mainly focused on the oxidative stress and mTOR signaling pathway. The alleviated effects of Forsythiaside on the reactive oxidative species accumulation and PRKCA and RHOA proteins upregulation in podocytes were also confirmed. Conclusion: The present study elucidates that Forsythiaside exerts potential treatment against DKD which may act directly RHOA and PRKCA target by suppressing the oxidative stress pathway in podocytes. And Forsythiaside could be regarded as one of the candidate drugs dealing with DKD in future experimental or clinical researches.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Xu, Miao, Chen and Zhang.

Use and reproduction: